GHRP-2: The Growth Hormone Secretagogue That Became an Actual Diagnostic Drug.

Most growth hormone secretagogues discussed in research circles never make it past preclinical work or small trials. GHRP-2 did something almost none of its siblings managed: it became an actual, licensed clinical product. Under the name pralmorelin, it's been approved in Japan since 2004 as a diagnostic agent for growth hormone deficiency — a genuinely rare distinction for a compound from the ghrelin-receptor secretagogue family, and one that gives GHRP-2 a considerably firmer human evidence base than most of the peptides it gets compared against.

GHRP-2, also known as pralmorelin or by its development codes GPA 748 and KP-102, is a synthetic hexapeptide developed out of the same research lineage that produced GHRP-6 — the pioneering work of endocrinologist Cyril Bowers, whose research group discovered in the 1980s that chemical analogues of met-enkephalin unexpectedly triggered growth hormone release from pituitary cells. GHRP-2 was engineered as a refinement of that original finding, optimised for greater potency and a cleaner secondary hormone profile than the compound that started the whole research line.

GHRP-2 is sold by Crown Peptides for laboratory research use only and has not been evaluated or approved by the FDA for human treatment.

The Sequence and the Mechanism

GHRP-2 is built from six amino acids: D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2. The substitution of D-2-naphthylalanine at the second position is the key structural difference from GHRP-6, replacing GHRP-6's tryptophan at that position with a bulkier aromatic naphthyl side chain. That single swap improves the peptide's hydrophobic contacts within the binding pocket of its target receptor, translating into meaningfully greater growth-hormone-releasing potency per dose.

Like GHRP-6, GHRP-2 works by activating the ghrelin receptor (GHS-R1a) on the pituitary gland, triggering growth hormone release through a pathway that's separate from, but converges with, the GHRH receptor pathway that compounds like sermorelin and tesamorelin activate. That converging-pathway relationship is why GHRP-2, like other ghrelin-receptor secretagogues, is frequently studied in combination with a GHRH analogue — activating both pathways together produces a growth hormone response considerably larger than either pathway alone.

The Accidental Discovery Behind the Whole Family

It's worth understanding how strange the original discovery behind GHRP-2 actually was, since it wasn't the product of a deliberate search for a growth-hormone-releasing compound. In 1984, Cyril Bowers and colleagues were investigating chemical analogues of met-enkephalin, an endogenous opioid peptide involved in pain signalling, when they observed that certain analogues unexpectedly triggered a strong growth hormone response in cultured pituitary cells — an effect entirely unrelated to opioid activity. That serendipitous finding launched an entirely new research direction, eventually identifying that these compounds were acting through a previously uncharacterised receptor rather than any opioid pathway. That receptor was only formally identified as the ghrelin receptor years later, once ghrelin itself was discovered as its endogenous ligand in 1999 — meaning the entire GHRP compound family, GHRP-2 included, was developed and used in human research for roughly fifteen years before scientists fully understood the receptor mechanism responsible for its effects.

GHRP-6 emerged first from that research programme as the original clinically studied hexapeptide. GHRP-2 followed as a deliberate refinement, developed jointly through work at Polygen in Germany and Tulane University in the US, specifically targeting greater potency and a somewhat cleaner secondary hormone profile than the founding compound. That refinement effort is what eventually produced a molecule potent and well-characterised enough to clear an actual regulatory approval process in Japan, two decades after Bowers' original serendipitous finding.

Why the Structural Modifications Actually Matter

GHRP-2's specific amino acid substitutions aren't arbitrary tweaks — each one addresses a particular limitation of simpler peptide structures. The D-amino acids at positions one, two, and five (D-Ala, D-2Nal, D-Phe) protect the peptide from rapid enzymatic degradation, since the body's proteolytic enzymes are generally built to recognise and cleave the L-amino-acid forms found in naturally occurring proteins — a D-amino acid at a cleavage site meaningfully slows that breakdown process. The naphthylalanine substitution at position two, GHRP-2's single biggest structural departure from GHRP-6, adds a large, flat aromatic ring system that fits more snugly into a hydrophobic pocket within the ghrelin receptor's binding site than GHRP-6's tryptophan does at the same position — the specific structural change responsible for GHRP-2's greater binding affinity and correspondingly greater potency.

Genuinely Potent: What the Human Data Shows

GHRP-2's potency isn't a marketing claim — it's a documented, measured finding. In healthy young adults, GHRP-2 administered at just 1 mcg/kg produced a growth hormone response that exceeded the response produced by the maximal effective dose of GHRH itself, a notable result given GHRH is the body's own native growth-hormone-releasing signal. Co-administration of GHRP-2 with a GHRH analogue has been shown to produce a synergistic effect, with combined growth hormone responses two to three times larger than either compound produces on its own — a pattern consistent with the two pathways converging on the same downstream pituitary output through separate receptors.

GHRP-2 was also shown, in some of the earliest human research on the compound, to retain meaningful growth-hormone-releasing activity when administered orally rather than by injection — an unusual property for a peptide, since most peptides are broken down by digestion before they can reach circulation intact. That oral activity, while considerably weaker than injected administration, was part of what made GHRP-2 and its close relatives attractive candidates for further clinical development in the first place.

From Research Compound to Licensed Diagnostic: The Japanese Approval

This is the detail that sets GHRP-2 apart from almost every other compound in the ghrelin-receptor secretagogue family. In October 2004, Japan's Pharmaceuticals and Medical Devices Agency approved pralmorelin as a diagnostic tool for assessing growth hormone deficiency in both children over four years old and adults, marketed by Kaken Pharmaceutical. That approval was supported by a pivotal Japanese multicentre trial testing 126 children across 84 facilities, using a single 100 mcg intravenous bolus dose. The trial established peak GH levels above 16 ng/mL in children and above 9 ng/mL in adults as the diagnostic cutoff values distinguishing normal pituitary function from growth hormone deficiency.

The diagnostic logic behind that use is straightforward: GHRP-2 reliably and sharply raises growth hormone levels in people with normal pituitary function, regardless of age, sex, or body weight. In someone with genuine growth hormone deficiency, that response is significantly blunted compared with healthy controls, giving clinicians a fast, single-dose functional test of pituitary GH-releasing capacity — a considerably more practical diagnostic tool than the older, slower stimulation tests it was designed to improve on.

It's worth being precise about what this approval does and doesn't mean. Pralmorelin is licensed in Japan specifically as a diagnostic agent — a tool for testing pituitary function — not as a treatment for growth hormone deficiency itself, and that approval doesn't extend to the UK, US, or EU, where GHRP-2 holds no licensed medical use of any kind. A parallel development effort in the United States, run by Wyeth investigating GHRP-2 as a treatment for growth hormone deficiency rather than a diagnostic tool, reached Phase II trials before being discontinued.

How GHRP-2 Compares to GHRP-6

The two compounds are close relatives, but they aren't interchangeable. Head-to-head research directly comparing the two has found GHRP-2 produces a faster and higher growth hormone peak than GHRP-6 at equimolar doses, making it the more potent of the pair on a straight per-microgram basis. GHRP-2 also carries a meaningfully cleaner secondary hormone profile: both compounds can produce transient, dose-dependent elevations in cortisol and prolactin alongside their intended growth hormone effect, but GHRP-2's effect on those secondary hormones is generally milder than GHRP-6's at comparable research doses. GHRP-6 also produces a considerably more intense appetite-stimulating effect, driven by direct ghrelin receptor activation in the hypothalamic arcuate nucleus, whereas GHRP-2's appetite stimulation is comparatively moderate.

That places GHRP-2 in an intermediate position on the selectivity spectrum within this compound family: less selective than newer secretagogues like ipamorelin, which was specifically engineered to minimise cortisol and prolactin effects almost entirely, but considerably more selective than GHRP-6, the original hexapeptide from which the whole family descends. Researchers choosing between GHRP-2 and GHRP-6 are generally trading GHRP-6's more pronounced secondary hormonal and appetite effects against GHRP-2's greater raw potency and comparatively cleaner profile.

Direct Comparison Data: GH, Prolactin, ACTH, and Cortisol

A frequently cited study by Arvat and colleagues, published in Peptides in 1997, directly compared GHRP-2 and hexarelin (a related synthetic secretagogue) against GHRH, TRH, and hCRH in human subjects, measuring the full hormonal response profile across growth hormone, prolactin, ACTH, and cortisol. That research helped establish the now-standard understanding that ghrelin-receptor secretagogues as a class produce a broader hormonal signature than GHRH alone — meaningful growth hormone release accompanied by smaller, generally self-limiting shifts in the other three hormones — a pattern distinct from GHRH's more narrowly targeted effect on growth hormone release alone.

Dosage in Research Settings

Research and clinical dosing for GHRP-2 varies considerably by application. The Japanese diagnostic protocol uses a single 100 mcg intravenous bolus dose specifically for its GH-stimulation test. Broader research use, outside the diagnostic context, has generally used doses in a similar range — commonly cited figures fall around 1-2 mcg/kg per administration, reflecting the potency data showing meaningful GH release even at very low doses. Those figures describe published research and clinical dosing under monitored conditions, not self-administration guidance.

Side Effects and Safety Considerations

GHRP-2's most consistently reported effects beyond growth hormone release are transient increases in cortisol and prolactin, generally milder than those seen with GHRP-6 but still present and dose-dependent. Moderate appetite stimulation is also commonly reported, consistent with its ghrelin-receptor activity, though less pronounced than GHRP-6's considerably stronger orexigenic effect. As a diagnostic agent used in a single-dose clinical protocol in Japan, its acute safety profile at diagnostic doses is reasonably well characterised; its safety profile under repeated, longer-term research dosing outside that single-dose diagnostic context is considerably less thoroughly documented in the published literature.

What the Diagnostic Approval Does and Doesn't Prove

It's worth being precise about what GHRP-2's regulatory history actually demonstrates, since it's easy to overstate. A diagnostic approval confirms that GHRP-2 reliably and reproducibly triggers a measurable, dose-dependent growth hormone response — genuinely useful evidence about its core pharmacology and acute safety at a defined single dose. It does not constitute evidence that GHRP-2 is safe or effective as a repeated-dose treatment for any condition, since the diagnostic protocol uses it as a one-time functional test rather than an ongoing therapy. The discontinued Wyeth programme investigating GHRP-2 as a treatment rather than a diagnostic tool is a useful reminder of that distinction: even a compound with a cleared regulatory pathway in one specific, narrow application didn't automatically clear the considerably higher bar required for approval as an ongoing therapeutic.

Why Research on This Compound Family Still Matters

GHRP-2's path from Bowers' original 1980s discovery work through to an actual licensed clinical diagnostic product is a useful illustration of how the whole ghrelin-receptor secretagogue field developed. GHRP-6 established that the mechanism worked at all. GHRP-2 refined it for greater potency and a somewhat cleaner profile, refined enough to clear a genuine regulatory approval process in at least one major market. Ipamorelin later refined the concept further still, prioritising selectivity above raw potency. Each compound in that lineage represents a different point on the same underlying engineering trade-off between GH-releasing strength and secondary hormonal noise, and GHRP-2's clinical approval history gives researchers an unusually well-documented reference point for understanding where that trade-off actually lands in human subjects, rather than relying purely on preclinical extrapolation.

Combination Protocols in Practice

Because GHRP-2 activates a pathway that converges with, rather than competes against, the GHRH receptor pathway, it's frequently studied alongside a GHRH analogue — sermorelin, tesamorelin, or non-DAC CJC-1295 among the options researchers pair it with. That combination logic mirrors the same pattern seen with ipamorelin and GHRP-6: two separate, converging inputs to the same pituitary output, studied together to capture the synergistic response neither pathway produces in isolation. GHRP-2's particular potency makes that synergy especially pronounced in published research, consistent with the two-to-threefold combined response reported when it's paired with a GHRH analogue rather than used alone.

Researchers choosing between GHRP-2 and ipamorelin as a combination partner for a GHRH analogue are generally weighing the same trade-off described earlier: GHRP-2's greater raw potency against ipamorelin's cleaner, more selective secondary hormone profile. Neither is a strictly better choice — the right compound depends on whether a given research design prioritises maximising the growth hormone signal or minimising confounding hormonal variables like cortisol and prolactin.

Manufactured to Research Standard

GHRP-2's six-amino-acid sequence, including its D-amino-acid and naphthylalanine modifications, requires careful synthesis verification to confirm the finished product matches its intended structure rather than containing truncated or incorrectly modified by-products.

Crown Peptides tests every batch of GHRP-2 for HPLC purity and mass spectrometry identity confirmation, with a batch-specific certificate of analysis provided for every order.GHRP-2 is also frequently studied alongside its close relative GHRP-6, both manufactured and verified to the same standard.

As with other short lyophilised peptides, GHRP-2 should be stored refrigerated at 2-8°C, protected from light and moisture before reconstitution, and — once reconstituted with bacteriostatic water — kept refrigerated and used within the supplier's stated window.

Quick Answers

What is GHRP-2? GHRP-2 (pralmorelin) is a synthetic hexapeptide that activates the ghrelin receptor to stimulate growth hormone release from the pituitary, refined from the original GHRP-6 hexapeptide for greater potency and a cleaner secondary hormone profile.

Is GHRP-2 an approved medicine anywhere? Yes — as pralmorelin, it's been approved in Japan since 2004 as a diagnostic agent for assessing growth hormone deficiency, though that approval doesn't extend to the UK, US, or EU and doesn't cover therapeutic use.

How does GHRP-2 compare to GHRP-6? GHRP-2 is generally more potent per dose and produces a milder cortisol, prolactin, and appetite response than GHRP-6, though it's still less selective than newer compounds like ipamorelin.

How potent is GHRP-2 compared with GHRH? A 1 mcg/kg dose exceeded the growth hormone response produced by the maximal effective dose of GHRH itself, and combining GHRP-2 with a GHRH analogue produces a synergistic response two to three times larger than either compound alone.

What dose was used in the pivotal diagnostic trial? A single 100 mcg intravenous bolus, the same dose used in the Japanese diagnostic protocol. Broader research use has generally applied lower per-administration doses around 1-2 mcg/kg.

The Bottom Line

GHRP-2 occupies a genuinely unusual position among research peptides: a compound with a real, licensed clinical use, even if that use is diagnostic rather than therapeutic and limited to a single market. Its potency, its synergy with GHRH analogues, and its comparatively cleaner secondary hormone profile relative to GHRP-6 make it one of the better-characterised compounds in the entire ghrelin-receptor secretagogue family — a useful reference point for researchers studying this whole class of compounds, not just GHRP-2 itself.

References

1. Pralmorelin [GPA 748, GHRP 2, Growth Hormone-Releasing Peptide 2, KP-102 D, KP-102 LN]. Drugs R D. 2004;5(4):236-239. https://doi.org/10.2165/00126839-200405040-00011
2. Arvat E, Di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885-891. https://pubmed.ncbi.nlm.nih.gov/9285939/